NOC vs TT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Northrop Grumman exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and strong profitability metrics, including an ROE of 26.17%. While the stock trades at a significant premium to its Graham Number ($277.28), it remains below its growth-based intrinsic value of $858.45. However, a very high PEG ratio of 5.05 and bearish insider activity suggest that the current price may be overextended relative to near-term growth. The outlook is balanced between strong aerospace demand and valuation headwinds.
Trane Technologies (TT) trades at a premium valuation with strong profitability and consistent earnings execution, outperforming peers on ROE and margin discipline despite elevated multiples. The company has delivered 21 of the last 25 quarters beating EPS estimates, with a 5-year return of +193.4%, reflecting durable shareholder value creation amid resilient HVAC demand and operational efficiency. While insider selling raises minor concerns, robust analyst conviction (18 analysts, Buy rating) and a healthy balance sheet support continued outperformance. TT’s growth trajectory and capital allocation discipline position it favorably within the industrials sector, particularly against lower-growth peers like 3M and underperforming Lockheed Martin.
Compare Another Pair
Related Comparisons
NOC vs TT: Head-to-Head Comparison
This page compares Northrop Grumman Corporation (NOC) and Trane Technologies plc (TT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.